Las Vegas Sands (NYSE: LVS) has recently received a number of price target changes and ratings updates: 12/27/2025 – Las Vegas Sands was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating. 12/24/2025 – Las Vegas Sands had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. […]

Several brokerages have updated their recommendations and price targets on shares of Tenet Healthcare (NYSE: THC) in the last few weeks: 12/27/2025 – Tenet Healthcare was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating. 12/22/2025 – Tenet Healthcare had its “hold (c+)” rating reaffirmed by analysts at Weiss […]

Several analysts have recently updated their ratings and price targets for Synaptics (NASDAQ: SYNA): 12/29/2025 – Synaptics had its price target raised by analysts at Northland Securities from $85.00 to $106.00. They now have an “outperform” rating on the stock. 12/28/2025 – Synaptics was upgraded by analysts at Wall Street Zen from a “hold” rating […]

Several brokerages have updated their recommendations and price targets on shares of Spire (NYSE: SR) in the last few weeks: 12/22/2025 – Spire had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings. 12/17/2025 – Spire had its price target raised by analysts at UBS Group AG from $95.00 to $100.00. They now have […]

Several brokerages have updated their recommendations and price targets on shares of First Internet Bancorp (NASDAQ: INBK) in the last few weeks: 12/25/2025 – First Internet Bancorp was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating. 12/22/2025 – First Internet Bancorp had its “sell (d)” rating reaffirmed by […]

Several analysts have recently updated their ratings and price targets for M&T Bank (NYSE: MTB): 12/22/2025 – M&T Bank had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings. 12/19/2025 – M&T Bank had its price target raised by analysts at Jefferies Financial Group Inc. from $235.00 to $250.00. They now have a “buy” […]

A number of firms have modified their ratings and price targets on shares of Equity Bancshares (NYSE: EQBK) recently: 12/22/2025 – Equity Bancshares had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings. 12/15/2025 – Equity Bancshares had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings. 12/15/2025 – Equity Bancshares was downgraded […]

HudBay Minerals (NYSE: HBM) recently received a number of ratings updates from brokerages and research firms: 12/23/2025 – HudBay Minerals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings. 12/17/2025 – HudBay Minerals was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating. 12/15/2025 – HudBay […]

Several analysts have recently updated their ratings and price targets for Fortune Brands Innovations (NYSE: FBIN): 12/22/2025 – Fortune Brands Innovations had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings. 12/15/2025 – Fortune Brands Innovations had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings. 12/8/2025 – Fortune Brands Innovations had its […]

A number of firms have modified their ratings and price targets on shares of Ovid Therapeutics (NASDAQ: OVID) recently: 12/27/2025 – Ovid Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating. 12/22/2025 – Ovid Therapeutics is now covered by analysts at Lifesci Capital. They set an “outperform” […]

A number of research firms have changed their ratings and price targets for Terns Pharmaceuticals (NASDAQ: TERN): 12/22/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings. 12/15/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings. 12/11/2025 – Terns Pharmaceuticals had its price target […]

Research Analysts’ price target changes for Monday, December 29th: Accenture (NYSE:ACN) had its price target trimmed by Argus from $370.00 to $335.00. Argus currently has a buy rating on the stock. Autolus Therapeutics (NASDAQ:AUTL) had its target price boosted by Needham & Company LLC from $10.00 to $11.00. The firm currently has a buy rating […]